
Originally Posted by
MuscleInk
It's a complex disease with well over 100 possible mutations up and downstream along various molecular pathways. In short, yes, the disease can be difficult to treat and like every other cancer, there are genomic differences in response rates. I recently gave a presentation on prostate cancer, androgen blockade, and hormone refractory disease.
Any growth peptide can cause hyperplasia and hypertrophy (increase in number and size of cells). If cells are mutagenic and proliferate (grow) disease spreads, hence the risk in using GH or growth-factor peptides. Let me be clear though, these peptides do NOT cause cancer, however they can (and likely do) accelerate the growth of cancerous cells.
Anabolic compounds bind to androgenic receptors (ARs). The prostate fossa is loaded with ARs and stimulation of these receptors will cause enlargement of prostate tissue and the potential for mutations to occur.
I've mentioned this numerous times on here but it rarely gets the attention it deserves.